212 related articles for article (PubMed ID: 34431136)
1. Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.
Goodman AM; Jeong AR; Phillips A; Wang HY; Sokol ES; Cohen PR; Sicklick J; Fajgenbaum DC; Kurzrock R
Eur J Haematol; 2021 Dec; 107(6):642-649. PubMed ID: 34431136
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
3. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
4. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
[TBL] [Abstract][Full Text] [Related]
7. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
8. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
9. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
10. Increased mTOR activation in idiopathic multicentric Castleman disease.
Arenas DJ; Floess K; Kobrin D; Pai RL; Srkalovic MB; Tamakloe MA; Rasheed R; Ziglar J; Khor J; Parente SAT; Pierson SK; Martinez D; Wertheim GB; Kambayashi T; Baur J; Teachey DT; Fajgenbaum DC
Blood; 2020 May; 135(19):1673-1684. PubMed ID: 32206779
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
[TBL] [Abstract][Full Text] [Related]
12. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
13. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
14. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.
Yu T; Cai QQ; Zhai QL; Li L; Fang X; Li J; Sun R; Yang H; Wang Z; Qian W; Xu-Monette ZY; Young KH; Yu L
Leuk Lymphoma; 2022 Dec; 63(13):3082-3091. PubMed ID: 36074798
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of Castleman Disease.
Simpson D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
[TBL] [Abstract][Full Text] [Related]
16. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
17. Genetic basis for iMCD-TAFRO.
Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.
González García A; Fernández-Martín J; Robles Marhuenda Á
Rheumatology (Oxford); 2023 Apr; 62(4):1426-1435. PubMed ID: 35997567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]